Comments for Pharma Strategy Blog

Comment on Stunning data with dabrafenib (BRAFV600E) in metastatic melanoma and brain metastases by Jody Schoger

Jody Schoger — Tue, 22 May 2012 19:16:00 +0000

Sally,
Thanks for writing this wonderful case up. Keeping fingers and toes crossed on this.
jms

Comment on My take on the crizotinib Xalkori FDA approval by Glc

Glc — Tue, 22 May 2012 16:10:00 +0000

I’ve been taking Xalkori for about 2 months since being diagnosed with stage 4 lung cancer in February, no conventional chemo or radiation prior to starting Pfizer’s pill. Other than occasional diarhea, and a slightly diminshed energy level and I tire more easily, so I’m getting close to 9 or 10 hours of sleep a night. Other than this, if i didn’t know i had cancer, I wouldn’t know i had cancer.
Saw an X-Ray after three weeks of treatment, and even in this crude resolution, diminished cancer was evident. Obviously evident, I’m pleased to say, although understand I’m a new cancer patient, untrained in analyzing x-rays. I can, however, tell black from white!
Looking forward to seeing a CT scan result in June for verification and a more accurate assessment.
Also saw on NBC news where Xaklori wiped out a child’s lymphoma in 28 days- results so amazing they made national TV news.
God bless al the aner researchers, for this patient is getting 95% of previous quality of life, heightened since I’m OT spending it 60 hours a week at work since i woke up to what is important in my life- because i feel I’ve been granted a second one with this treatment.

Comment on ASCO 2012 Preview – Highlights of key data emerging from Chicago by maverickny

maverickny — Wed, 16 May 2012 19:59:00 +0000

Thanks Roberto, glad you liked it. Always nerve wracking picking possible hot topics without seeing the abstracts, but still fun to do.

Comment on ASCO 2012 Preview – Highlights of key data emerging from Chicago by maverickny

maverickny — Wed, 16 May 2012 19:58:00 +0000

Hematology drugs rarely get much attention at ASCO unless the data is in the plenary or in the press briefing, Peter. Methinks you’ll have to wait for ASH in December

Comment on ASCO 2012 Preview – Highlights of key data emerging from Chicago by Biomaven

Biomaven — Wed, 16 May 2012 14:12:00 +0000

Ibrutinib (PCI-32765), Pharmacyclic’s BTK inhibitor should also justifiably get a lot of attention.
Peter

Comment on ASCO 2012 Preview – Highlights of key data emerging from Chicago by Roberto

Roberto — Wed, 16 May 2012 02:25:00 +0000

Thank you Sally. I was looking forward to this and as always you delivered brilliantly!

Roberto (@scimegaresearch)

Comment on ASCO 2012 Acronym Mania! by Guest

Guest — Mon, 14 May 2012 23:54:00 +0000

That is such a creative way to present something! Love it Sally You could apply this creative presentation in so many ways couldn’t you. I expect it helps people remember it better too.

Comment on Risk of lung cancer after treatment for breast cancer by seo services america

seo services america — Mon, 14 May 2012 08:04:00 +0000

Really great examples regarding testing share.Thanks for sharing such article with us.Keep sharing always article like this in future too.

Comment on On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer by Holandadelgado

Holandadelgado — Sun, 06 May 2012 16:47:00 +0000

for people with long cancer mesothelioma if taking xalkori if not works what others options can they have

Comment on Ribonucleases (RNase) – clinical applications for cancer therapy by Office

Office — Fri, 04 May 2012 13:22:00 +0000

Really interesting and informative post. I will read the other posts of you as well. Thank you for sharing such a valuable information with us.